Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes
Hemogenyx Pharmaceuticals (LSE:HEMO) has secured £285,000 through the issuance of convertible loan notes (CLNs) to support its clinical trial of HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukemia. The funding comes primarily from existing shareholders.
The CLNs will automatically convert at a fixed price of £3.00 per share, expected around March 8, 2025. Subscribers will receive one-for-one warrants exercisable at £4.00 per share, valid for 15 months from March 1, 2025. The conversion shares will be admitted to trading on the London Stock Exchange, with admission expected by March 15, 2025.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha ottenuto £285.000 attraverso l'emissione di note di prestito convertibili (CLN) per supportare il suo trial clinico di HG-CT-1, una terapia CAR-T per la leucemia mieloide acuta in recidiva o refrattaria. Il finanziamento proviene principalmente da azionisti esistenti.
Le CLN si convertiranno automaticamente a un prezzo fisso di £3,00 per azione, previsto intorno all'8 marzo 2025. Gli abbonati riceveranno warrant uno a uno esercitabili a £4,00 per azione, validi per 15 mesi a partire dal 1 marzo 2025. Le azioni di conversione saranno ammesse alla negoziazione sulla Borsa di Londra, con ammissione prevista entro il 15 marzo 2025.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha conseguido £285,000 mediante la emisión de notas de préstamo convertibles (CLNs) para apoyar su ensayo clínico de HG-CT-1, una terapia CAR-T para la leucemia mieloide aguda en recaída o refractaria. La financiación proviene principalmente de accionistas existentes.
Las CLNs se convertirán automáticamente a un precio fijo de £3.00 por acción, previsto alrededor del 8 de marzo de 2025. Los suscriptores recibirán warrants uno a uno ejercitables a £4.00 por acción, válidos por 15 meses a partir del 1 de marzo de 2025. Las acciones de conversión serán admitidas a negociación en la Bolsa de Valores de Londres, con admisión prevista para el 15 de marzo de 2025.
Hemogenyx Pharmaceuticals (LSE:HEMO)는 재발성 또는 불응성 급성 골수성 백혈병을 위한 CAR-T 세포 치료제인 HG-CT-1의 임상 시험을 지원하기 위해 전환 가능한 대출 노트(CLN)를 발행하여 £285,000을 확보했습니다. 자금은 주로 기존 주주들로부터 나왔습니다.
CLN은 자동으로 전환됩니다 고정 가격 £3.00로 주당, 2025년 3월 8일 경에 예상됩니다. 구독자는 주당 £4.00에 행사 가능한 1:1 워런트를 받게 되며, 2025년 3월 1일부터 15개월 유효합니다. 전환 주식은 런던 증권 거래소에서 거래될 예정이며, 2025년 3월 15일까지 상장될 것으로 예상됩니다.
Hemogenyx Pharmaceuticals (LSE:HEMO) a sécurisé 285 000 £ grâce à l'émission de billets de prêt convertibles (CLN) pour soutenir son essai clinique de HG-CT-1, une thérapie CAR-T pour la leucémie myéloïde aiguë en rechute ou réfractaire. Le financement provient principalement d'actionnaires existants.
Les CLN se convertiront automatiquement à un prix fixe de 3,00 £ par action, prévu autour du 8 mars 2025. Les souscripteurs recevront des bons de souscription échangeables au ratio de 1:1 à 4,00 £ par action, valables pendant 15 mois à compter du 1er mars 2025. Les actions de conversion seront admises à la négociation sur la Bourse de Londres, avec une admission prévue d'ici le 15 mars 2025.
Hemogenyx Pharmaceuticals (LSE:HEMO) hat £285.000 durch die Ausgabe von wandelbaren Anleihen (CLNs) gesichert, um seine klinische Studie von HG-CT-1, einer CAR-T-Zelltherapie für rezidivierende oder refraktäre akute myeloische Leukämie, zu unterstützen. Die Finanzierung stammt hauptsächlich von bestehenden Aktionären.
Die CLNs werden automatisch umgewandelt zu einem festen Preis von £3,00 pro Aktie, erwartet um den 8. März 2025. Die Zeichner erhalten Warrants im Verhältnis 1:1, die zu £4,00 pro Aktie ausgeübt werden können und 15 Monate ab dem 1. März 2025 gültig sind. Die Umwandlungsaktien werden an der Londoner Börse gehandelt, mit einer Zulassung, die bis zum 15. März 2025 erwartet wird.
- Secured £285,000 in additional funding for clinical trials
- Strong support from existing shareholders demonstrates confidence in company strategy
- Extended financial runway through CLN issuance
- Dilutive effect on existing shareholders through CLN conversion
- Company requires additional funding to complete clinical development
LONDON, UK / ACCESS Newswire / February 19, 2025 / NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
19 February 2025
HEMOGENYX PHARMACEUTICALS PLC
("Hemogenyx Pharmaceuticals" or the "Company")
Issue of convertible loan notes to raise £285,000
Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised £285,000 through the issue of convertible loan notes (the "CLNs"). As the Company prepares to treat the first patient in the clinical trial of HG-CT-1, its CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, it was approached by an investor group, primarily composed of existing shareholders, offering to provide funding to support its clinical trial. Further updates on the clinical trial will be provided in the near future.
Convertible Loan Notes
To support the clinical trial, the Company is pleased to announce it has raised £285,000 (before expenses) through the issuance of convertible loan notes (the "CLNs") at a fixed conversion price of £3.00 per share.
The CLNs, which are non-interest bearing, will automatically convert following an increase in the Company's headroom restrictions under the FCA's Prospectus Rules, allowing for the issuance of conversion shares without requiring an approved prospectus. This conversion is expected to take place on or shortly after 8 March 2025.
Subscribers will also receive a one-for-one warrant, exercisable at a price of £4.00 per share for each share held upon the CLN conversion date (the "Warrants").
Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, commented:
"We are very pleased with the progress of the clinical trials for our lead product, HG-CT-1. We are also grateful for the strong support from our subscribing noteholders, the majority of whom are existing shareholders. I believe this reflects their confidence in our strategy and long-term vision.
"We believe the CLNs are in the best interest of our shareholders, as it extends the Company's financial runway. The Board believes that the commencement of the clinical trial has significantly strengthened the Company's position and created new opportunities to secure the funding needed to complete clinical development."
Warrants
Each CLN subscriber will be issued one Warrant per conversion share on the conversion date, which is expected to occur on or shortly after 8 March 2025, in accordance with the terms of the CLN. The Warrants will have an exercise price of £4.00 per share and will remain valid for 15 months from 1 March 2025.
Application for Admission
The Company will apply for the admission of the Ordinary Shares, issued to subscribers upon the conversion of the CLNs, to trading on the London Stock Exchange. Admission is expected to become effective on 15 March 2025.
Upon admission, the new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares and will be entitled to receive all future dividends and distributions declared, paid, or made on the Company's ordinary share capital.
Enquiries:
Hemogenyx Pharmaceuticals plc |
| |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
| |
Peter Redmond, Director |
| |
|
|
|
SP Angel Corporate Finance LLP |
| Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
|
|
Peterhouse Capital Limited |
| Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
What is the conversion price for Hemogenyx's (HOPHF) new convertible loan notes?
When will Hemogenyx's (HOPHF) new convertible loan notes convert to shares?
What are the terms of the warrants issued with Hemogenyx's (HOPHF) convertible notes?
How much funding did Hemogenyx (HOPHF) raise through the convertible loan notes?
When will Hemogenyx's (HOPHF) new conversion shares begin trading?
